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A propensity score matched comparison of different insulin
regimens 1 year after beginning insulin in people with type
2 diabetes
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Aim: To compare using propensity score analysis the outcome of beginning insulin therapy with basal, premix, mealtime+ basal or mealtime
insulin on the basis of data from 3031 people from the observational CREDIT (Cardiovascular Risk Evaluation in People with Type 2 Diabetes on
Insulin Therapy) study. This approach overcomes likely confounding in baseline and unknown characteristics common to observational studies.
Methods: Efficacy and safety outcomes were collected at baseline and at 1 year in previously insulin-naı¨ve people. Propensity score matched
groups using all available baseline data were defined to compare outcomes by pairs of insulin regimens.
Results: From 2659 people with available data, propensity score matches were achieved for 686 people starting premix or basal insulin,
542 starting basal+mealtime or premix insulin and 400 starting basal or basal+mealtime. HbA1c reduction did not differ between the
three pairs of insulin regimens. However, the relative risk of overall and nocturnal hypoglycaemia was lower (p= 0.010 to p< 0.001) with
basal or basal+mealtime compared with premix insulin, and for nocturnal (p= 0.021) but not overall hypoglycaemia for basal compared to
basal+mealtime insulin. Body weight increase was less for basal versus premix insulin [–1.3 (95% CI –2.1, –0.6) kg, p< 0.001] or versus
basal+mealtime insulin [–1.4 (–2.5, –0.3) kg, p= 0.016], but did not differ between basal+mealtime and premix. Smaller groups matching
mealtime insulin had some residual mismatching of HbA1c.
Conclusion: Comparing insulin regimens between individuals matched by propensity scores indicated differences in hypoglycaemia and body
weight change, despite similar HbA1c reductions. Our findings are consistent with those from randomized controlled trials.
Keywords: CREDIT study, HbA1c, hypoglycaemia, insulin regimens, propensity score
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Introduction
Guidelines, including evidence-based guidelines, from various
health-care organizations recommend glucose control targets
in people with type 2 diabetes (T2DM) [1–3]. When metformin
and other oral therapies can no longer attain glucose control tar-
gets, it is generally recommended that insulin therapy be started.
Recommendations as to insulin type vary. Some authorities
endorse both basal and premix approaches, and others place
more emphasis on basal insulin; mealtime insulin alone is used
on occasion, or in a comprehensive basal + mealtime regimen
even from the time of starting insulin [1–3].
Randomized clinical trials (RCTs), such as the Treat to Target
in Type 2 Diabetes (4-T) trial [4], have provided evidence on
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the relative efficacy of insulin regimens, but these trials were
conducted in people and clinical environments that may not be
representative of those in real-world clinical practice. Although
randomized trials maximize internal validity, it is likely that a
range of selection biases will exist in relation to the recruitment
and retention of patients in trials. Analyses based on non-
interventional observational studies may overcome some of the
challenges of generalizability inherent in randomized trials and
may be used as a bridge from randomized trials towards more
real-world settings. Propensity score matching may overcome
some of the limitations of observational studies of therapies in
terms of internal validity [5], although properly randomized
studies are the only design that can ensure unbiased results,
albeit in an artificial setting. Hence it is informative to consider
the results of both kinds of studies.
The Cardiovascular Risk Evaluation in People with Type 2
Diabetes on Insulin Therapy (CREDIT) study, an international
4-year, non-interventional, longitudinal study, was designed to
evaluate, in routine clinical practice, the relationship between
blood glucose control and cardiovascular (CV) events in people
treated with insulin and to provide insight into current,
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real-world practices of the use of insulin in people with
T2DM. Here we report blood glucose-related outcomes at
1 year and use propensity score matched analyses to compare
the performance of different insulin regimens.
Methods
The CREDIT study design, site and participant selection process
and participant baseline characteristics have been reported
previously [6]. Briefly, the study involved 314 centres in 12
countries, 10 in Europe, plus centres in Canada and Japan.
Eligibility criteria were: men and women with T2DM, aged
>40 years, who had started insulin therapy (any type or
supplier) within 12 months prior to study entry and who had
an HbA1c measurement within the 3 months before starting
insulin. As a non-interventional study, there was no fixed study
visit schedule, and insulin choice, dosage, titration, funding and
concomitant oral agent therapy were according to usual local
practice. Data were gathered in routine clinical practice, with
the treating physicians asked to report updated participant data
on a 6-month cycle. Data at the ’1-year’ follow-up represents
that provided during the 9–18 months after beginning insulin.
Ethical approval according to local regulations was obtained
for all study sites. Conduct of the study adhered to standards of
data collection for clinical trials, according to the Declaration
of Helsinki. Written informed consent was obtained from all
participants before commencement of data collation.
To assess glucose control-related outcomes, we studied
HbA1c, fasting plasma glucose (FPG), postprandial plasma
glucose (PPPG), symptomatic hypoglycaemic episodes (over-
all), nocturnal hypoglycaemic events, body weight increase and
switching to alternative insulin therapy.
Statistical Analysis
Data are analysed and reported by descriptive statistics using
sas software (v 9.2; Cary, NC, USA). Propensity score-matched
cohorts were used to assess blood glucose control outcomes
(as above) by pairs of insulin regimens: basal, mealtime,
basal + mealtime and premix (giving six possible pairings). No
distinction was made between analogue and human insulins.
The propensity score analysis was performed by one of the
authors (N. F.). Proc GLIMMIX in sas (v 9.2) was used to
develop propensity scores used as the basis for the selection
of propensity score-matched cohorts. Each propensity score
included the following baseline explanatory variables which
could potentially be related with treatment allocation: age,
sex, time since diagnosis of diabetes, weight, BMI, baseline
HbA1c, use of biguanides, dipeptidyl peptidase (DPP)-4
inhibitors, glinides, glucagon-like peptide (GLP)-1 receptor
agonists, sulfonylureas, thiazolidinediones and geographical
region; we also included the number (count) of glucose-
lowering drugs (other than insulin), α-adrenergic blockers,
angiotensin 2 receptor blockers/ACE inhibitors, anticoagulants,
antiplatelet agents, β-adrenergic blockers, calcium channel
blockers, diuretics, fibrates, statins, vasodilators (including
nitrates). The intention was to achieve precise matching for
patient characteristics in matched cohorts, as selection biases
might confound comparisons between the treatment strategies.
An optimal matching algorithm (dist macro in sas) was used
to match participants within the two groups, using a precise
matching criterion (<0.01) for the principal analyses between
treated pairs on the propensity score.
Once the propensity score-matched cohorts were estab-
lished, baseline demographic and clinical characteristics were
tabulated in the format described for the whole population.
Matched cohorts were compared using generalized mixed mod-
els with appropriate error terms and link functions, with
investigator sites included as random effects and where appro-
priate, baseline characteristics of the participants as explanatory
variables.
Missing data were not imputed. Pair-matched cohorts are
described using available baseline characteristics, and are
compared for glucose-related outcomes at 1 year using methods
analogous to those used in randomized trials. Sensitivity
analyses were conducted using a more stringent matching
criterion on the propensity scores (0.001).
Results
Participant Disposition
At the 1-year follow-up, data were available for 2734 (90.2%) of
the 3031 participants in the population analysed at baseline. Of
the 297 with no 1-year data, 239 had no follow-up information
available within the time window and 58 withdrew before 1-year
data were collected, because of participant request (n = 13),
lost to follow-up (n = 15), death (n = 14), investigator request
(n = 2) and other (n = 14).
Insulin and Oral Agent Regimens
The use of premix and basal + mealtime insulin therapy
increased after 1 year, whereas the use of basal insulin and
mealtime insulin declined (figure 1). A small proportion of
participants (2.3%) were no longer taking insulin after 1 year.
In all, 75.0% of participants remained on their initial regimen,
with the highest percentage in the premix group (85.4%) and
the lowest on mealtime insulin alone (37.6%). Insulin dose
increased from 20.0 (s.d. 14.6) U/day when starting insulin to
35.7 (25.5) U/day at 1 year (Table 1).
There was a trend towards the use of fewer oral
glucose lowering medications at 1 year, with the largest
decrease occurring with sulfonylureas (from 43.4 to 30.5%
of participants). Compared to baseline, fewer participants were
taking two oral medications (30.4 to 23.9%) and more were
taking one (35.7 vs. 33.0%) or none (36.2 vs. 30.0%) after a
year.
Overall Efficacy and Safety
Mean HbA1c declined by –1.9% (2.1) units [–21 (23)
mmol/mol] from 9.5% (2.0) [80 (22) mmol/mol], over the
year (Table 1), a change largely accounted for by the fall in
FPG of –3.6 (4.0) mmol/l, although PPPG also fell by –4.7
(4.9) mmol/l. Only 32.1% of participants achieved an HbA1c
<7%. In the 6 months before the 1-year visit, symptomatic
hypoglycaemia was reported by 20.1% of participants, and
nocturnal hypoglycaemia by 2.0% of participants (Table 1).
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Table 1. Baseline and 1-year metabolic outcomes in people with type 2 diabetes beginning insulin therapy in routine clinical practice.
Baseline 1 year Change p
n 3031 2734 2481
Insulin dose, U/day 20.0 (14.6) 35.8 (25.6) 15.7 (23.7) <0.001
HbA1c, % units 9.5 (2.0) 7.7 (1.4) –1.9 (2.1) <0.001
mmol/mol 80 (22) 61 (15) –21 (23) <0.001
HbA1c by initial insulin regimen, % units
Basal (N = 1326, 1291, 1264)* 9.3 (1.8) 7.7 (1.4) –1.5 (1.9) <0.001
Basal + mealtime (N = 392, 387, 379)* 10.0 (2.2) 7.5 (1.5) –2.5 (2.5) <0.001
Mealtime only (N = 98, 197, 192)* 9.4 (2.0) 7.3 (1.2) –2.1 (2.0) <0.001
Premix (N = 603, 577, 568)* 9.8 (2.0) 7.8 (1.4) –2.0 (2.2) <0.001
Other (N = 82, 83, 78)* 9.2 (1.9) 7.6 (1.5) –1.5 (2.1) <0.001
Fasting plasma glucose, mmol/l 11.6 (3.7) 7.9 (2.5) –3.6 (4.0) <0.001
Postprandial plasma glucose, mmol/l 14.2 (4.5) 9.6 (3.2) –4.7 (4.9) <0.001
Body weight, kg 79.8 (18.9) 81.4 (18.6) 1.7 (4.8) <0.001
Blood pressure
Systolic, mmHg 138.7 (19.1) 136.5 (16.9) –2.3 <0.0001
Diastolic, mmHg 80.8 (11.6) 78.9 (10.3) –1.9 <0.0001
Plasma lipids
Total cholesterol, mmol/l 5.2 (1.4) 4.9 (1.3) –0.4 (1.3) <0.001
LDL cholesterol, mmol/l 2.9 (0.9) 2.7 (0.8) –0.2 (0.9) <0.001
HDL cholesterol, mmol/l 1.3 (0.4) 1.3 (0.4) 0.0 (0.3) 0.11
Triglycerides, mmol/l 2.1 (2.4) 1.7 (1.4) –0.4 (2.5) <0.001
Hypoglycaemia in previous 6 months
Overall
People with ≥1 event, % 19.8
Rate, events/patient-years 2.2 (9.7)
Nocturnal
People with ≥1 event, % 7.9
Rate, events/patient-years 0.4 (2.0)
Mean (s.d.) unless otherwise stated.
* Number of participants at 1 year with HbA1c values at baseline, at 1 year, and at both times for change from baseline, respectively.
Figure 1. Proportion of people using specified insulin regimens at
initiation and 1 year.
Body weight increased by 1.7 kg (4.8). Blood pressure, total
cholesterol, low-density lipoprotein (LDL)-cholesterol and
triglycerides declined modestly, although reaching statistically
significance, while high-density lipoprotein (HDL) cholesterol
was unchanged (Table 1).
Comparison of Insulin Regimens
There were 2659 subjects who started insulin and had data
that enabled their inclusion in the analysis: basal insulin alone,
1355; basal + mealtime insulin, 400; mealtime insulin alone,
204; premix insulin, 613; and other insulin, 87.
Basal Insulin versus Premix. A propensity score match was
achieved for 343 people starting premix with 343 starting basal
insulin (Table 2). In general, the pair groups were well matched,
but there was some residual difference in region, where fewer
people from Southern Europe were treated with premix (25%)
versus basal (38%) (Table 2). The final insulin regimen at 1 year
showed some evolution towards basal + mealtime and premix
in those starting basal insulin, but was more stable (p < 0.001)
on those starting premix (Table 3). Use of basal insulin was
associated with a lower insulin dose and fewer injections than
with premix insulin (Table 3).
There was no difference in the fall of HbA1c over 1 year
between these insulins (Table 3), accounting for baseline
HbA1c and investigational sites as random effects. Weight
gain was 1.3 kg greater with premix, whereas there were fewer
overall and nocturnal hypoglycaemic episodes among those
treated with basal insulin (Table 3). There was no difference on
any criterion using tighter matching criteria (0.001), but only
155 people were included in each insulin regimen group after
propensity score matching.
Basal+Mealtime versus Premix. A match was achieved for
271 people starting basal + mealtime with 271 starting premix
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Table 2. Baseline characteristics of the larger propensity matched groups.
Basal versus premix Basal + mealtime versus premix Basal versus basal + mealtime
Basal Premix p Basal + mealtime Premix p Basal Basal + mealtime p
n 343 343 271 271 200 200
Age, years 61.3 (10.1) 61.3 (9.5) 0.98 59.4 (9.9) 61.1 (9.7) 0.045 62.1 (9.8) 59.4 (9.7) 0.005
Diabetes duration, years 10.4 (6.8) 9.7 (6.7) 0.22 9.6 (7.4) 10.9 (7.7) 0.043 10.8 (7.0) 9.3 (7.1) 0.037
Female, n (%) 165 (48.1) 177 (51.6) 0.40 151 (55.7) 128 (47.2) 0.059 108 (54.0) 122 (61.0) 0.19
Body weight, kg 82.2 (18.6) 82.4 (18.2) 0.90 77.4 (18.4) 76.9 (18.7) 0.72 79.1 (17.4) 82.2 (17.1) 0.069
BMI, kg/m2 29.8 (6.0) 30.2 (6.3) 0.38 26.7 (6.0) 28.2 (6.1) 0.34 29.3 (5.6) 30.4 (5.9) 0.040
HbA1c, % 9.4 (2.0) 9.7 (2.0) 0.10 10.1 (2.1) 10.0 (1.9) 0.77 9.5 (2.4) 9.8 (2.2) 0.18
mmol/mol 79 (22) 83 (22) 87 (23) 86 (21) 80 (27) 84 (24)
Prescriptions, n 9.7 (3.0) 9.5 (3.2) 0.32 9.9 (2.5) 9.6 (2.8) 0.28 9.7 (2.9) 9.6 (2.6) 0.69
α-Glucosidase inhibitor, n (%) 14 (4.1) 20 (5.8) 0.38 7 (2.6) 25 (9.2) 0.002 10 (5.0) 5 (2.5) 0.29
Biguanide, n (%) 185 (53.9) 185 (53.9) 1 70 (25.8) 88 (32.5) 0.11 85 (42.5) 71 (35.5) 0.18
DPP-4 inhibitor, n (%) 0 (0) 0 (0) 1 0 (0) 0 (0) 1 0 0 1
Glinides, n (%) 12 (3.5) 18 (5.3) 0.36 2 (0.7) 4 (1.5) 0.69 4 (2.0) 2 (1.0%) 0.69
GLP-1 receptor agonist, n (%) 0 (0) 0 (0) 1 0 (0) 0 (0) 1 0 (0) 0 (0) 1
Sulphonylurea, n (%) 125 (36.4) 127 (37.0) 0.94 33 (12.2) 51 (18.8) 0.043 51 (25.5) 44 (22.0) 0.48
Thiazolidinediones, n (%) 25 (7.3) 30 (8.8) 0.57 6 (2.2) 25 (9.3) <0.001 11 (5.5) 3 (1.5) 0.053
Region 0.006 <0.001 0.08
North America, n (%) 30 (8.8) 46 (13.4) 8 (3.0) 29 (10.7) 18 (9.0) 7 (3.5)
Eastern Europe, n (%) 115 (33.5) 125 (36.4) 95 (35.1) 71 (26.2) 71 (35.5) 88 (44.0)
Southern Europe, n (%) 129 (37.6) 87 (25.4) 86 (31.7) 49 (18.1) 76 (38.0) 78 (39.4)
Northern Europe, n (%) 52 (15.2) 61 (17.8) 20 (7.4) 41 (15.1) 20 (10.0) 20 (10.0)
Japan, n (%) 17 (5.0) 24 (7.0) 62 (22.9) 81 (29.9) 15 (7.5) 7 (3.5)
Mean (s.d.) unless otherwise stated.
insulin (Table 2). In general, the two treatment groups were
well matched, but there were some residual differences in
age and duration of diabetes, while again fewer people from
Southern Europe were treated with premix (18%) (Table 2).
Final insulin regimen showed some evolution towards basal
alone and premix in those starting basal + mealtime insulin, but
was more stable (p < 0.001) on those starting premix (Table 3).
Use of premix insulin was associated with a lower insulin dose
and fewer injections than with the multiple injection regimen
(Table 3).
There was no difference in the fall of HbA1c or change
in body weight over 1 year between these two insulin
regimens (Table 3). However, there were fewer overall and
nocturnal hypoglycaemic episodes among those treated with
basal + mealtime insulins (both p < 0.001, Table 3). At the
tighter level of matching, there were no statistically significant
differences in outcomes for the 79 people per treatment group.
Basal versus Basal+Mealtime. A match was achieved for 200
people starting basal insulin with 200 starting basal + mealtime
insulin (Table 2). In general, the groups were well matched,
but there were some residual differences in age, duration of
diabetes, body weight and BMI. The final insulin regimen at
1 year showed some evolution towards basal + mealtime and
premix in those starting on basal insulin, and towards basal
alone (12%) in those starting on a multiple injection regimen
(overall change between insulins p = 0.034) (Table 3). Use of
basal insulin was associated with a lower insulin dose and fewer
injections than with basal + mealtime (Table 3).
There was no difference in the fall of HbA1c over 1 year
between these two insulin regimens (Table 3). Despite the
higher baseline weight for the basal + mealtime regimen,
there was more weight gain (1.4 kg). While there was no
difference in overall hypoglycaemic episodes, the relative risk of
nocturnal episodes was lower on the basal + mealtime regimen
(p = 0.021) (Table 3). At the tighter level of matching (0.001),
there were only 67 people in each group. Similar results were
found except for a lack of difference in weight gain between the
two groups.
Comparisons of Mealtime-Only Insulin to Other Insulins. For
the three propensity score-matched cohorts involving mealtime
insulin alone, numbers were smaller: 244 in the premix group
(122 in each), 214 for basal + mealtime and 154 for basal alone
(Table 4). While matching was generally good, there were some
regional differences, and imbalances in baseline HbA1c, varying
from 6 mmol/mol (0.5 %) versus premix to 9 mmol/mol (0.8 %)
versus basal. Thus, while HbA1c (baseline adjusted) appeared
to fall more with both premix and basal than mealtime insulin
regimens, this may reflect the lower starting levels on mealtime
alone (Table 5). Numerically, overall hypoglycaemia was less
frequent on mealtime alone than on premix or the multiple
injection regimen, as was nocturnal hypoglycaemia compared
to premix. Body weight changes did not differ (Table 5). With
already lower numbers in these three comparisons involving
mealtime insulin alone, tighter matching reduced these further
and removed comparative differences in outcomes.
Discussion
We developed propensity score-matched comparisons of
patients with a similar observed likelihood of being treated
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Table 3. Comparisons for insulin dose and outcomes for the larger propensity matched groups.
Basal versus premix Basal + mealtime versus premix Basal versus basal + mealtime
Basal Premix p Basal + mealtime Premix p Basal Basal + mealtime p
n 343 343 271 271 200 200
Insulin dose, U/day 30 [18, 46] 39 [26, 52] <0.001 40 [25,56] 34 [21, 50] 0.006 30 [20, 44] 46 [32, 61] <0.001
Number of injections 2 [1, 2] 2 [2, 2] 0.003 4 [3, 4] 2 [2, 2] <0.001 2 [1, 2] 4 [4, 4] <0.001
Final insulin regimen, n
(%)
Basal 252 (73.5) 16 (4.7) 33 (12.2) 8 (3.0) 141 (70.5) 24 (12.0)
Basal + mealtime 46 (13.4) 23 (6.7) 188 (69.4) 16 (5.9) 29 (14.5) 160 (80.0)b
None 5 (1.5) 8 (2.3) 15 (5.5) 4 (1.5) 2 (1.0) 4 (2.0)
Premix 40 (11.7) 296 (86.3)a 31 (11.4) 242 (89.3)a 27 (13.5) 11 (5.5)
Short-acting 0 (0) 0 (0) 4 (1.5) 1 (0.4) 1 (0.5) 1 (0.5)
HbA1c, change (%
units)
–1.7 (2.0) –1.8 [2.0] –2.5 (2.4) –2.2 (2.2) –1.8 (2.3) –2.1 (2.3)
difference (95% CI) –0.0 (–0.2, 0.2] 0.99 –0.2 (–0.5, 0.10) 0.19 0.1 (–0.2, 0.4) 0.68
Body weight change, kg 1.2 (4.5) 2.3 (4.9) 2.2 (5.4) 2.7 (4.9) 1.5 (4.7) 2.7 (5.5)
difference (95% CI) –1.3 (–2.1, –0.6) <0.001 –0.1 (–1.2, 0.9) 0.78 –1.4 (–2.5, –0.3) 0.016
Hypoglycaemia
All,
events/patient-years
2.3 (9.0) 3.0 (10.0) 1.8 (4.9) 3.2 (10.5) 1.7 (5.5) 1.7 (4.8)
RR (95% CI) 0.7 (0.6, 0.9) <0.001 0.6 (0.5, 0.8) <0.001 1.3 (0.9, 1.7) 0.14
Nocturnal,
events/patient years
0.5 (1.8) 0.8 (4.2) 0.2 (1.1) 0.6 (3.9) 0.5 (1.7) 0.3 (1.2)
RR (95% CI) 0.6 (0.5, 0.9) 0.010 0.3 (0.2, 0.6] <0.001 2.0 (1.1, 3.5) 0.021
Data for insulin dose and number of injections are median [IQ range]; others are mean (s.d.), or as stated.
Difference in subjects remaining on initial insulin regimen: ap < 0.001; bp = 0.034.
with a particular insulin regimen, comparing those patients
who commenced that strategy against those with similar
characteristics who commenced the regimen being compared.
Analogous to the unbiased approach used in randomized
trials, we adopted the intention to treat principle in which we
compared strategies of treatment, allowing patients to change
therapy based upon their clinical need during follow-up in the
study.
In the CREDIT study, blood glucose control in this group of
well-resourced countries was disappointingly poor at the time
of starting insulin (Table 1), but consistent with reports from
primary health care in the UK [7,8], and with global data from
less well-resourced countries [9]. The improvement in blood
glucose control at 1 year in terms of HbA1c, FPG and PPPG
was clinically useful. However, because of high baseline levels
a minority of those studied attained a satisfactory HbA1c of
7.0 %. This again seems to reflect problems in diabetes care
in routine practice, for dose titration over 1 year was only to
some 36 U/day, while overall 75% of people remained on their
initial insulin regimen. The problem cannot be attributed to
hypoglycaemia, which in the last 6 months was experienced by
only 20% of those studied (and only 2% experienced severe
hypoglycaemia). Body weight gain of less than 2 kg on average
would also not seem to be an explanation. It appears that
barriers to starting insulin therapy might not be eliminated
even after it has been begun [10,11].
In randomized controlled trials, usually of specific insulin
types or regimens, larger reductions in HbA1c have been
reported from baseline levels which bracket those reported here
[12,13]. However in those studies, active insulin dose titration
was used, and the achieved insulin doses for some regimens
were more than double those found here, with more weight
gain and hypoglycaemia. Where people had better baseline
levels, as in the UK multicentre 4 T study [4], falls in HbA1c
were less with any regimen, but glucose was better controlled
at 12 months and with a similar increment in insulin dose to
our study. Taken together it appears that in routine clinical
practice, such as in the centres studied here, results as good as in
the RCTs were obtained. However, the opportunity for better
performance by starting at more respectable HbA1c levels, and
by titration of doses and regimens if good control was not
obtained, was missed. Similar conclusions were reached in a
shorter (24 weeks) observational study in a broader cohort of
less well-resourced countries [9]. In that study, however, the
lack of body weight gain and paucity of hypoglycaemia were
attributed to educational initiatives being implemented at the
same time insulin was started.
In general, in observational studies it is not appropriate
to make statistical comparisons of different therapies because
of confounding factors in their use. These can for example
be regular parts of clinical practice (e.g. metformin is started
in different circumstances from thiazolidinediones), differing
clinical habits in different countries (e.g. use of basal or premix
insulin most commonly) or more subtle effects (choice of
insulin regimen for people started on insulin as in-patients
in the context of other illness). Here, by including a range of
baseline diabetes and risk measures we have defined propensity-
matched sets between pairs of insulin types/regimens, but
can only validate this matching by comparison of those
same characteristics. Not surprisingly, we failed to achieve
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Table 4. Baseline characteristics of the smaller propensity matched groups.
Premix versus mealtime Basal + mealtime versus mealtime Basal versus mealtime
Premix Mealtime p Basal + mealtime Mealtime p Basal Mealtime p
n 122 122 107 107 77 77
Age, years 61.8 (10.6) 62.6 (8.7) 0.53 60.9 (11.1) 62.4 (8.8) 0.29 60.7 (10.0) 62.4 (9.1) 0.28
Diabetes duration, years 11.8 (7.7) 11.0 (7.8) 0.41 10.6 (8.0) 10.4 (7.9) 0.84 11.2 (6.7) 11.6 (8.6) 0.74
Female, n (%) 49 (40.2) 47 (38.5) 0.90 50 (46.7) 35 (32.7) 0.050 36 (46.8) 35 (45.5) 1
Body weight, kg 73.4 (17.8) 70.4 (17.7) 0.19 70.8 (18.9) 67.0 (16.5) 0.11 77.8 (17.2) 76.3 (18.5) 0.60
BMI, kg/m2 27.0 (5.6) 26.2 (5.4) 0.22 26.4 (6.1) 25.0 (4.9) 0.068 28.2 (5.4) 27.9 (5.7) 0.79
HbA1c, % 9.8 (1.8) 9.3 (1.9) 0.031 10.2 (2.2) 9.5 (1.9) 0.009 9.3 (2.0) 8.5 (1.5) 0.003
mmol/mol 84 (20) 78 (21) 88 (24) 80 (21) 78 (22) 69 (17)
Prescriptions, n 9.8 (2.5) 10.4 (1.8) 0.029 10.0 (2.4) 10.3 (1.5) 0.27 9.7 (2.7) 10.4 (2.1) 0.061
α-Glucosidase inhibitor, n (%) 14 (11.5) 11 (9.0) 0.67 6 (5.6) 9 (8.4) 0.59 4 (5.2) 9 (11.7) 0.25
Biguanide, n (%) 39 (32.0) 42 (34.4) 0.79 15 (14.0) 23 (21.5) 0.21 35 (45.5) 41 (53.3) 0.42
DPP-4 inhibitor, n (%) 0 (0%) 0 (0%) 1 0 (0) 0 (0) 1 0 (0) 0 (0) 1
Glinides, n (%) 3 (2.5) 6 (4.9) 0.50 1 (0.9) 1 (0.9) 1 4 (5.2) 7 (9.1) 0.53
GLP-1 receptor agonist, n (%) 0 (0%) 0 (0%) 1 0 (0) 0 (0) 1 0 (0) 0 (0) 1
Sulphonylurea, n (%) 26 (21.3) 28 (23.0) 0.88 6 (5.6) 14 (13.1) 0.098 23 (29.9) 24 (31.2) 1
Thiazolidinediones, n (%) 8 (6.6) 11 (9.0) 0.63 3 (2.8) 5 (4.7) 0.72 8 (10.4) 8 (10.4) 1
Region 0.002 0.040 0.28
North America, n (%) 8 (6.6) 5 (4.1) 2 (1.9) 3 (2.8) 3 (3.9) 5 (6.5)
Eastern Europe, n (%) 26 (21.3) 11 (9.0) 21 (19.6) 9 (8.4) 21 (27.3) 11 (14.3)
Southern Europe, n (%) 14 (11.4) 32 (26.2) 17 (15.9) 25 (23.4) 28 (36.4) 33 (42.9)
Northern Europe, n (%) 16 (13.1) 12 (9.8) 8 (7.5 3 (2.8) 14 (18.2) 12 (15.6)
Japan, n (%) 58 (47.5) 62 (50.8) 59 (55.1) 67 (62.6) 11 (14.3) 16 (20.8)
Mean (s.d.), unless otherwise stated.
a satisfactory match for some pairs of treatments, suggesting
the insulins were being used in quite different circumstances,
but this occurred in general where best possible pair matching
resulted in fewer pairs, again as might be expected. Although
we included measures of baseline frailty, in particular age,
treatment for CV disease and body mass, it is useful to
consider the likely direction of a bias should unexplained
patient frailty lead to a systematic difference in the selection
of diabetes regimen. It seems likely that such a bias revealed
in patients initiating insulin would be expressed as a tendency
to subject frailer patients to less intrusive regimens. Thus we
might anticipate that any bias would be against basal insulin.
Nevertheless, apparently valid comparisons were obtained for
basal versus premix, basal versus multiple injection therapy and
mealtime alone versus premix. While some mismatch occurred
for the first for region, this was largely for southern Europe and
then only by 13% of the total population. The effect disappeared
with tighter matching, without affecting conclusions, but this
meant a much smaller test population with lower statistical
power.
The finding of similar glucose control (as HbA1c) with
basal and premix insulin, despite lower insulin dose, differs
from the 4 T study at 1 year where insulin detemir did less
well than analogue premix despite similar dose titration [4].
However, in our study we were not aware of the mix of
different basal and premix insulins, human or analogue, or
type/manufacturer. More consistent, however, is the finding
that there was less hypoglycaemia, in particular nocturnal
hypoglycaemia, and less weight gain, with the basal insulin
than premix [4,12]. When basal insulin was compared with
a basal + mealtime regimen there was also no difference in
HbA1c despite lower insulin dose. However, the short-acting
insulin in this regimen is then associated with more weight gain,
although still not clinically large (mean 1.4 kg making 2.7 kg
in all). Overall hypoglycaemia did not differ, but nocturnal
hypoglycaemia, though low in frequency, was more frequent
with basal insulin, perhaps indicating that in some individuals
pushing the dose too hard when short-acting insulin is required
can give problems at night. These data are consistent with that of
the basal + mealtime versus premix comparison, where HbA1c
and body weight change did not differ despite higher dose with
the multiple injection regimen, but hypoglycaemia remained
less frequent.
The mealtime insulin alone comparisons are more
troublesome, owing to smaller paired groups for our primary
outcome variable of interest, HbA1c. As a result the greater
drops in HbA1c in two of the comparisons may simply have
been due to higher starting levels or to residual confounders
in the datasets. In these circumstances it is probably unwise to
conclude anything about the apparent differences in relative
risk of hypoglycaemia.
Our study has limitations. Lack of the strict site monitoring
that usually occurs in RCTs may have resulted in missed or
inaccurate information, for example of hypoglycaemia where
recall is known to be a problem. Although non-interventional
and with retrospective entry of baseline data, we cannot exclude
the possibility that investigators started insulin on occasion in
the knowledge that the patient could be entered into the
study. Nevertheless, clearly the baseline HbA1c level shows
that insulin was indicated in the overwhelming majority.
The grouping of insulins into categories which implies that
both human and anologue insulins may be included in the
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Table 5. Comparisons for insulin dose and outcomes for the smaller propensity matched groups.
Premix versus mealtime Basal + mealtime versus mealtime Basal versus mealtime
Premix Mealtime p Basal + mealtime Mealtime p Basal Mealtime p
n 122 122 107 107 77 77
Insulin dose, U/day 30 [18,50] 24 [14, 36] 0.004 22 [13, 33] 27 [19, 44] 0.005 23 [16, 39] 27 [16, 40] 0.95
Number of injections 2 [2, 2] 3 [2, 4] <0.001 4 [2, 4] 3 [2, 4] 0.42 1 [1, 2] 3 [2, 4] <0.001
Final insulin regimen, n
(%)
Basal 2 (1.6) 5 (4.1) 13 (12.2) 4 (3.7) 58 (75.5)a 3 (3.9)
Basal + mealtime 4 (3.3) 36 (29.5) 58 (54.2)b 30 (28.0) 11 (14.3) 29 (37.7)
None 1 (0.8) 7 (5.7) 8 (7.5) 4 (3.7) 1 (1.3) 3 (3.9)
Premix 115 (94.3)a 30 (24.6) 25 (23.4) 29 (27.1) 6 (7.8) 10 (13.0)
Short-acting 0 (0) 44 (36.1) 3 (2.8) 40 (37.4) 1 (1.3) 32 (41.6)
HbA1c, change (%
units)
–2.2 (2.1) –2.1 (2.1) –2.8 (2.5) –2.3 (2.1) –1.5 (1.9) –1.3 (1.9)
difference (95% CI) 0.4 (0.05, 0.7) 0.025 0.2 (–0.2, 0.6) 0.25 0.6 (0.2, 1.0) 0.008
Body weight change, kg 2.0 (4.7) 1.2 (5.6) 1.6 (5.1) 1.6 (5.9) 0.7 (3.6) 1.1 (5.9)
difference (95% CI) 0.9 (–0.4, 2.3) 0.17 0.4 (–1.2, 2.0) 0.63 –0.3 (–1.9, 1.3) 0.74
Hypoglycaemia
All
(events/patient-years)
3.2 (12.4) 1.5 (3.7) 3.0 (10.2) 1.4 (3.6) 0.3 (0.9) 0.3 (1.1)
RR (95% CI) 2.1 (1.3, 3.4) 0.002 3.3 (2.3, 4.8) <0.001 1.2 (0.7, 2.0) 0.50
Nocturnal
(events/patient-years)
0.4 (2.0) 0.1 (0.9) 0.1 (0.5) 0.1 (0.9) 0.1 (0.4) 0.1 (0.6) 1.0
RR (95% CI) 3.2 (1.3, 7.5) 0.009 0.8 (0.3, 2.8) 0.76 1.0 (0.3, 3.0)
Data for insulin dose and number of injections are median [IQ range]; others are mean (s.d.), or as stated. Difference in subjects remaining on initial
insulin regimen: ap < 0.001; bp = 0.025.
same category enables adequate numbers of subject in each
insulin per group, and was also required by regulatory bodies.
However this approach may obfuscate benefits of a specific
regimen as part of an ‘average’ effect with a less successful
insulin. While the propensity analysis is a powerful tool for
pair matching groups to remove possible hidden confounders
in the data, by its very nature it is not possible to validate
fully the success of this analysis. Furthermore it is clear
from the smaller ill-matched groups that such confounders
do exist in the original dataset, confirming our caution in
not comparing insulins without propensity pair-matching, and
providing support for the approach we have taken over others
that involve attempting statistical adjustment for difference in
patient characteristics (which would have compared patients
who did not share characteristics in our excluded analyses). A
strength and limitation of the propensity score approach is that
it constrains comparisons to subjects with a similar likelihood of
receiving a treatment based upon their observed characteristics.
This means that the number of subjects actually included in
matched comparisons is smaller than that available. While
ensuring that we do not compare unalike patients, based upon
the observed characteristic that they have equal likelihood to be
treated with the either regimen, the consequence is that subjects
are discarded where they do not share an equal likelihood of
either treatment option. The propensity score approach may
thus in our setting be considered to provide a good basis for
comparison between the treatments but only for those subjects
for whom there exists a similar likelihood to receive either
therapy.
In conclusion, insulin therapy delivers in routine clinical
practice the gains described from RCTs, and without major
problems of hypoglycaemia (except in a small minority)
and without large amounts of weight gain. Basal insulin at
1 year outperforms premix insulin in terms of weight gain and
hypoglycaemia, although the differences are not large. A more
complex mealtime + basal regimen gives uncertain advantage
in glucose control, but with extra weight gain. Persistence of use
of mealtime insulin alone is poor. In routine clinical practice
insulin is still started late, and dose titration often remains
inadequate.
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